BioTech IP Review

Publication Number: WO 2025043209A1
Filing Date (Provisional Priority): August 24 2023 & November 7 2023 (U.S. provisional filings)
Publication Date: March 2025
Assignee: Listed generically (not necessarily Retro Biosciences; but conceptually tied to aging biomarkers)

What the Application Covers

This published patent application relates to epigenetic biomarker technology based on the methylation status of endogenous retroelements (such as specific retroviral sequences and LINE‑1 elements in the human genome).

Key points of the technology described:

• Retroelements & aging: Uses methylation states at specific CpG loci within retroelements (e.g., HERVs and LINE‑1 sequences) to determine biological or epigenetic age of a subject.
• Epigenetic clocks: Provides methods to compute biological age estimates, which are more predictive of physiological aging than chronological age.
• Diagnostic & monitoring uses: Covers methods to assess aging, monitor therapeutic effects, and evaluate responses to anti‑aging interventions based on changes in methylation patterns.
• Potential interventions: Includes suggested use of antiretroviral therapies or other interventions to treat age‑associated diseases, rejuvenate tissues, or reduce epigenetic age based on these biomarkers.

This sort of epigenetic biomarker technology — especially built around retroelements — is critical for longevity biotech because it gives a molecular measure of aging and treatment impact, not merely disease state.

---

Why This Is Important

• Aligns with core mission: Retro Biosciences’ public mission is identifying and intervening in aging mechanisms to extend healthy lifespan. An epigenetic clock based on retroelement methylation is a quantitative tool to measure biological age and treatment efficacy.
• Supports clinical development: If Retro or a partner were to adopt or license such technology, it could be instrumental in measuring outcomes in trials like those for their autophagy‑enhancing drug RTR242 in Alzheimer’s and aging studies.
• Broad application: Epigenetic biomarkers can be used for diagnostics, patient stratification, and regulatory endpoints across aging, neurodegeneration, and age‑related diseases — all therapeutic areas Retro is pursuing.
• Commercial leverage: Successfully granted patents in this domain could give competitive advantage for diagnostic/biomarker services or companion diagnostics alongside Retro’s therapeutic candidates.